Paul Chaplin, who led Bavarian Nordic for more than 30 years, announced his departure months after a proposed $3 billion takeover by private equity collapsed last November. The management change follows a high‑profile acquisition attempt that did not materialize and comes amid strategic scrutiny of the vaccine specialist’s direction. The exit opens a leadership search at a company known for commercial vaccines and late‑stage programs. Investors and industry partners will monitor succession plans and any shift in strategic priorities tied to R&D or potential future M&A. A change at the top during a period of takeover interest may also affect Bavarian Nordic’s market positioning and potential transaction discussions moving forward.